These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22047156)

  • 1. Phenotypic analysis of HIV-1 genotypic drug-resistant isolates from China, using a single-cycle system.
    Jia Z; Xu S; Nie J; Li J; Zhong P; Wang W; Wang Y
    Mol Diagn Ther; 2011 Oct; 15(5):293-301. PubMed ID: 22047156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discordance between genotypic resistance and pseudovirus phenotypic resistance in AIDS patients after long-term antiretroviral therapy and virological failure.
    Yang J; Geng W; Zhang M; Han X; Shang H
    J Basic Microbiol; 2014 Oct; 54(10):1120-5. PubMed ID: 24338739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotype and phenotype patterns of drug-resistant HIV-1 subtype B' (Thai B) isolated from patients failing antiretroviral therapy in China.
    Ma L; Sun J; Xing H; Si X; Yuan L; Guo Y; Cheng H; Shao Y
    J Acquir Immune Defic Syndr; 2007 Jan; 44(1):14-9. PubMed ID: 17019361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis of the association of H208Y and thymidine analogue resistance mutations M41L, L210W and T215Y in the HIV-1 reverse transcriptase of treated patients.
    Betancor G; Nevot M; Mendieta J; Gómez-Puertas P; Martínez MA; Menéndez-Arias L
    Antiviral Res; 2014 Jun; 106():42-52. PubMed ID: 24667336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Research on the selective kinetics of HIV-1 nucleoside reverse transcriptase inhibitor drug resistance-associated mutations among 4 AIDS patients receiving highly active antiretroviral therapy].
    Li J; Jiao LY; Li HP; Li L; Liu YJ; Zhuang DM; Liu SY; Bao ZY; Li H; Wang Z; Li JY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Aug; 29(8):794-800. PubMed ID: 19103117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors.
    Clark SA; Shulman NS; Bosch RJ; Mellors JW
    AIDS; 2006 Apr; 20(7):981-4. PubMed ID: 16603849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of susceptibility of HIV-1 variants to antiretroviral drugs by genotypic and recombinant virus phenotypic analyses.
    Chang S; Zhuang D; Li J; Liu S; Li H; Han J; Li L; Liu Y; Bao Z; Li T; Song H; Zhang W
    Int J Infect Dis; 2015 Aug; 37():86-92. PubMed ID: 26117343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil.
    Cerqueira DM; Amorim RM; Silva RR; Camara GN; Brígido MM; Martins CR
    Mem Inst Oswaldo Cruz; 2004 Dec; 99(8):877-82. PubMed ID: 15761606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.
    Parikh UM; Bacheler L; Koontz D; Mellors JW
    J Virol; 2006 May; 80(10):4971-7. PubMed ID: 16641288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
    Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
    J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
    Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.
    Betancor G; Garriga C; Puertas MC; Nevot M; Anta L; Blanco JL; Pérez-Elías MJ; de Mendoza C; Martínez MA; Martinez-Picado J; Menéndez-Arias L; ; Iribarren JA; Caballero E; Ribera E; Llibre JM; Clotet B; Jaén A; Dalmau D; Gatel JM; Peraire J; Vidal F; Vidal C; Riera M; Córdoba J; López Aldeguer J; Galindo MJ; Gutiérrez F; Álvarez M; García F; Pérez-Romero P; Viciana P; Leal M; Palomares JC; Pineda JA; Viciana I; Santos J; Rodríguez P; Gómez Sirvent JL; Gutiérrez C; Moreno S; Pérez-Olmeda M; Alcamí J; Rodríguez C; del Romero J; Cañizares A; Pedreira J; Miralles C; Ocampo A; Morano L; Aguilera A; Garrido C; Manuzza G; Poveda E; Soriano V
    Retrovirology; 2012 Aug; 9():68. PubMed ID: 22889300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.
    Whitcomb JM; Huang W; Limoli K; Paxinos E; Wrin T; Skowron G; Deeks SG; Bates M; Hellmann NS; Petropoulos CJ
    AIDS; 2002 Oct; 16(15):F41-7. PubMed ID: 12370521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative--Uganda.
    Weidle PJ; Downing R; Sozi C; Mwebaze R; Rukundo G; Malamba S; Respess R; Hertogs K; Larder B; Ochola D; Mermin J; Samb B; Lackritz E
    AIDS; 2003 Jul; 17 Suppl 3():S39-48. PubMed ID: 14565608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-loop recombinant pseudotyped-virus-based assay to detect HIV-1 phenotypic resistance.
    Wu S; Yan P; Yan Y; Qiu L; Xie M
    Arch Virol; 2015 Jun; 160(6):1385-95. PubMed ID: 25795166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.
    Lafeuillade A; Poggi C; Hittinger G; Chadapaud S
    HIV Med; 2001 Oct; 2(4):231-5. PubMed ID: 11737402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug resistance evolution in patients with human immunodeficiency virus-1 under long-term antiretroviral treatment-failure in Yunnan Province, China.
    Li J; Xu Y; Liu J; Yang B; Yang C; Zhang M; Dong X
    Virol J; 2019 Jan; 16(1):5. PubMed ID: 30621727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.
    Muñoz M; Carmona R; Pérez-Alvarez L; Cilla G; Suarez MD; Delgado E; Contreras G; Corral J; de Goicoetxea MJ; Medrano L; Lezaún MJ; Nájera R;
    J Clin Virol; 2005 Jul; 33(3):224-9. PubMed ID: 15911444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of genotypic resistance to nucleoside analogues, nonnucleoside analogues, and protease inhibitors in HIV-infected persons in Athens, Greece.
    Panos G; Charatsis G; Paparizos V; Kazantzi M; Falagas ME
    AIDS Res Hum Retroviruses; 2008 Jan; 24(1):43-51. PubMed ID: 18275347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.